Pages
- Adcirca®
- Adcirca® FAQ
- Aironite®
- Ambrisentan
- BiPAP / CPAP
- Bosentan
- Calcium Channel Blockers
- Coumadin®
- Digitalis
- Diuretics
- Endothelin Receptor Antagonists
- Epoprostenol for Injection
- Epoprostenol sodium
- Flolan®
- Iloprost
- Inhaled Treprostinil
- INOmax®
- Jantoven®
- Letairis®
- Macitentan
- Marfarin®
- Nitric Oxide
- Opsumit®
- Other Drugs and Treatments
- Oxygen
- Phosphodiesterase type-5 Inhibitor
- Prostacyclin
- PTE
- Remodulin®
- Revatio®
- Riociguat
- Sildenafil Citrate
- Sitaxsentan Sodium
- Tadalafil
- Thelin®
- Tracleer®
- Tracleer® FAQ
- Transplant
- Treprostinil
- Tyvaso®
- Under FDA Review
- Veletri®
- Ventavis®
- Viagra®
- Volibris®
- Warfarin
Warfarin (Coumadin®,Jantoven®,Marfarin®)
Warfarin is used to prevent blood clots from forming or growing larger in your blood and blood vessels. It is prescribed for people with certain types of irregular heartbeat, people with prosthetic (replacement or mechanical) heart valves, and people who have suffered a heart attack. Warfarin is also used to treat or prevent venous thrombosis (swelling and blood clot in a vein) and pulmonary embolism (a blood clot in the lung). Warfarin is in a class of medications called anticoagulants ('blood thinners'). It works by decreasing the clotting ability of the blood.
How administered
Warfarin is an oral medication in pill form. The dosage and administration of Warfarin must be individualized for each patient according to the particular patient's PT/INR response to the drug. The dosage should be adjusted based upon the patient's PT/INR
Risks/Side Effects
The most serious risks associated with anticoagulant therapy with Warfarin is hemorrhage in any tissue or organ
Call your doctor at once if you have any of these serious side effects:
Call your doctor at once if you have any of these serious side effects:
- skin changes or discoloration anywhere on your body;
- purple toes or fingers;
- pain in your stomach, back, or sides;
- low fever, loss of appetite, dark urine, jaundice (yellowing of the skin or eyes);
- diarrhea, fever, chills, body aches, flu symptoms;
- easy bruising or bleeding that will not stop;
- blood in your urine;
- black, bloody, or tarry stools;
- nosebleeds, bleeding gums, coughing up blood;
- feeling weak or light-headed;
- sudden headache, confusion, problems with vision, speech, or balance;
- sudden leg or foot pain; or
- sudden numbness or weakness, especially on one side of the body.
Less serious side effects may include:
- nausea, vomiting, stomach pain;
- gas and bloating; or
- hair loss.
Pathway
Warfarin acts by inhibiting the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of γ-carboxyglutamic acid residues in the proteins which are essential for biological activity.
Costs
The price of PT/INR monitoring is a factor that must be considered when determining the total cost of treatment. Prices vary considerably.
Additional info
The traditional anticoagulants that have been in use for the prevention or treatment of thromboembolic disease are heparin, as well as it’s various analogues, and warfarin. There are two major drawbacks to these medications: a narrow dosage range that provides adequate anticoagulation without bleeding, and a highly individualized response to various doses among individuals that requires fairly frequent monitoring by laboratory testing.
In recent years, several types of anticoagulants and antiplatelets have been developed or studied to help overcome these drawbacks. Although few of these have been studied, and none have been FDA approved as conjunctive treatment for PH, your doctor still might prescribe them if he/she feels that they are a better option in your particular case. We are providing links to more information on these medications here for your convenience.
The classes of anticoagulants include:
- Factor Xa inhibitors
Rivaroxaban
Apixaban
- Direct thrombin inhibitors
Bivalirudin (Angiomax)
Argatroban
Dabigatran (Pradaxa)
The classes of antiplatelet drugs include:
- Irreversible cyclooxygenase inhibitors
Aspirin
- Adenosine diphosphate (ADP) receptor inhibitors:
Clopidogrel (Plavix)
Prasugrel (Effient)
Ticagrelor (Brilinta)
Ticlopidine (Ticlid)
- Adenosine reuptake inhibitors
Dipyridamole (Persantine)
- Phosphodiesterase inhibitors
Cilostazol (Pletal)
- Glycoprotein IIB/IIIA inhibitors
Abciximab (ReoPro)
Eptifibatide (Integrilin)
Tirofiban (Aggrastat)
In recent years, several types of anticoagulants and antiplatelets have been developed or studied to help overcome these drawbacks. Although few of these have been studied, and none have been FDA approved as conjunctive treatment for PH, your doctor still might prescribe them if he/she feels that they are a better option in your particular case. We are providing links to more information on these medications here for your convenience.
The classes of anticoagulants include:
- Factor Xa inhibitors
Rivaroxaban
Apixaban
- Direct thrombin inhibitors
Bivalirudin (Angiomax)
Argatroban
Dabigatran (Pradaxa)
The classes of antiplatelet drugs include:
- Irreversible cyclooxygenase inhibitors
Aspirin
- Adenosine diphosphate (ADP) receptor inhibitors:
Clopidogrel (Plavix)
Prasugrel (Effient)
Ticagrelor (Brilinta)
Ticlopidine (Ticlid)
- Adenosine reuptake inhibitors
Dipyridamole (Persantine)
- Phosphodiesterase inhibitors
Cilostazol (Pletal)
- Glycoprotein IIB/IIIA inhibitors
Abciximab (ReoPro)
Eptifibatide (Integrilin)
Tirofiban (Aggrastat)
Visit the FDA Page for this drug/therapy
Page Reviewed/Edited: June 2012
In The News
- April 16, 2013
Dabigatran 'as good as warfarin' claim authors of ‘real-world’ study- September 9, 2012
- Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation
- September 3, 2012
- Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension.
- August 18, 2012
- No Profound Difference Between Oral Anticoagulants, Comparison Suggests
- July 8, 2012
- Rivaroxaban for the Treatment of Pulmonary Embolism
- June 30, 2012
- Rivaroxaban for the Treatment of Pulmonary Embolism
- June 23, 2012
- Pharmacodynamic Properties of Antiplatelet Agents
- June 18, 2012
- Aspirin vs warfarin: which is better?
- April 3, 2012
- Man Dies from Reported Pradaxa Side Effects
- February 12, 2012
- Close INR Monitoring Needed When Warfarin Users Add an Antibiotic
- January 22, 2012
- Head Trauma Victims on Blood Thinners Need Repeat CT
- January 15, 2012
- Anticoagulation Patient Self-monitoring in the United States
- December 10, 2011
- Anticoagulation Self-Monitoring Halves Thromboembolic Risk
- November 26, 2011
- Fewer INR Checks Safe in Patients on Stable-Dose Warfarin
- November 19, 2011
- Rivaroxaban, Dabigatran, or Warfarin?
- November 5, 2011
- New and Emerging Anticoagulant Therapy for Atrial Fibrillation and Acute Coronary Syndrome
- October 9, 2011
- An Effective Warfarin Alternative?
- September 10, 2011
- Effect of Acetaminophen on International Normalized Ratio in Patients Receiving Warfarin Therapy
- March 27, 2011
- Another Contender in the Race to Unseat Warfarin
- February 19, 2011
- One Lot of Warfarin Recalled
- February 13, 2011
- Pradaxa in Bottles Must Be Used Within 30 Days
- February 11, 2011
- New Drug Helps Patients With Atrial Fibrillation
- November 7, 2010
- Dabigatran Q&A: The Who, When, and How for Switching, Starting, and Stopping the New Oral Anticoagulant
- October 27, 2010
- Heart2Heart: The end of the road for the rat poison?
- February 5, 2010
- New Oral Anticoagulants on the Horizon

.jpg)